Süleyman Çetinkünar1, Hasan Erdem1, Recep Aktimur2, Mehmet Aziret3, Sabri Özdaş4, Banu Yürekli5, Fahri Yetişir6. 1. Clinic of General Surgery, Adana Numune Training and Research Hospital, Adana, Turkey. 2. Clinic of General Surgery, Samsun Training and Research Hospital, Samsun, Turkey. 3. Clinic of General Surgery, Kars State Hospital, Kars, Turkey. 4. Clinic of General Surgery, Adıyaman Training and Research Hospital, Adıyaman, Turkey. 5. Department of Endocrinology, Ege University Faculty of Medicine, İzmir, Turkey. 6. Clinic of General Surgery, Atatürk Training and Research Hospital, Ankara, Turkey.
Abstract
OBJECTIVE: Bariatric surgery with multidisciplinary management is a more effective method to treat morbid obesity and obesity-related comorbidities compared with nonsurgical treatments. Laparoscopic sleeve gastrectomy (LSG) was initially performed as the first stage of biliopancreatic diversion with duodenal switch in the super-obese population. In the past few years, however, LSG has been performed as a definitive procedure because of its promising early and midterm results. The aim of this study is to evaluate the efficacy of our initial LSG series of 73 patients on excess weight loss (EWL) and resolution of obesity-related comorbidities in short-term follow-up. MATERIAL AND METHODS: From March 2013 to May 2014, 78 morbid obese patients with an average body mass index (BMI) of 46.3 kg/m(2) underwent LSG. There is a 9-month follow-up period on average. Five patients were excluded from the study, because they could not be contacted. Comorbidities, preintervention BMI, glucose, HbA1c, and lipid profiles were recorded at 1, 6, and 12 months postintervention. RESULTS: After the surgery, the percent EWL was 58%. The mean serum glucose level, HbA1c level, LDL-cholesterol level, triglyceride level, insulin, and insulin resistance decreased significantly and the mean HDL-cholesterol level increased. CONCLUSION: For the resolution of comorbidities, LSG may be used as an effective bariatric and metabolic surgery.
OBJECTIVE: Bariatric surgery with multidisciplinary management is a more effective method to treat morbid obesity and obesity-related comorbidities compared with nonsurgical treatments. Laparoscopic sleeve gastrectomy (LSG) was initially performed as the first stage of biliopancreatic diversion with duodenal switch in the super-obese population. In the past few years, however, LSG has been performed as a definitive procedure because of its promising early and midterm results. The aim of this study is to evaluate the efficacy of our initial LSG series of 73 patients on excess weight loss (EWL) and resolution of obesity-related comorbidities in short-term follow-up. MATERIAL AND METHODS: From March 2013 to May 2014, 78 morbid obesepatients with an average body mass index (BMI) of 46.3 kg/m(2) underwent LSG. There is a 9-month follow-up period on average. Five patients were excluded from the study, because they could not be contacted. Comorbidities, preintervention BMI, glucose, HbA1c, and lipid profiles were recorded at 1, 6, and 12 months postintervention. RESULTS: After the surgery, the percent EWL was 58%. The mean serum glucose level, HbA1c level, LDL-cholesterol level, triglyceride level, insulin, and insulin resistance decreased significantly and the mean HDL-cholesterol level increased. CONCLUSION: For the resolution of comorbidities, LSG may be used as an effective bariatric and metabolic surgery.
Authors: N Basso; D Capoccia; M Rizzello; F Abbatini; P Mariani; C Maglio; F Coccia; G Borgonuovo; M L De Luca; R Asprino; G Alessandri; G Casella; F Leonetti Journal: Surg Endosc Date: 2011-06-03 Impact factor: 4.584
Authors: David Nocca; Fabre Guillaume; Patrick Noel; Marie Christine Picot; Rajesh Aggarwal; Moez El Kamel; Roxanne Schaub; Charles de Seguin de Hons; Eric Renard; Jean Michel Fabre Journal: Obes Surg Date: 2011-06 Impact factor: 4.129
Authors: María José Aguilar-Cordero; Raquel Rodríguez-Blanque; Cristina Levet Hernández; Javiera Inzunza-Noack; Juan Carlos Sánchez-García; Jessica Noack-Segovia Journal: J Clin Med Date: 2022-08-08 Impact factor: 4.964